| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2013PLoSO...881489Z |
| P356 | DOI | 10.1371/JOURNAL.PONE.0081489 |
| P932 | PMC publication ID | 3839930 |
| P698 | PubMed publication ID | 24282600 |
| P5875 | ResearchGate publication ID | 258956326 |
| P2093 | author name string | Yong-Tang Zheng | |
| Liu-Meng Yang | |||
| Rong-Hua Luo | |||
| Xing-Jie Zhang | |||
| Rui-Rui Wang | |||
| Yue-Ping Wang | |||
| Yan-Ping He | |||
| Li-He Lu | |||
| Christopher Cong Lai | |||
| P2860 | cites work | Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants | Q39895940 |
| Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later | Q40005181 | ||
| Synthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarbonylmethylthio)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors | Q40014152 | ||
| Preparation and characterization of three monoclonal antibodies against HIV-1 p24 capsid protein. | Q40113621 | ||
| Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity | Q40342543 | ||
| TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. | Q40425001 | ||
| Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase | Q40790038 | ||
| Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series | Q41110624 | ||
| Synthesis and anti-HIV-1 activity of thio analogues of dihydroalkoxybenzyloxopyrimidines. | Q41309346 | ||
| TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments | Q42033549 | ||
| Near full-length genomic characterization of a novel HIV type 1 subtype B/C recombinant strain from Yunnan, China | Q46182378 | ||
| 5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile | Q46481272 | ||
| Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 V | Q57480046 | ||
| Synthesis, Biological Activity, and ADME Properties of Novel S-DABOs/N-DABOs as HIV Reverse Transcriptase Inhibitors | Q60197481 | ||
| [In vitro selection and identification of HIV strain which is resistance to two new HIV-1 nonnucleoside reverse transcriptase inhibitors] | Q83476569 | ||
| 5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives | Q28370647 | ||
| A comprehensive mapping of HIV-1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic survey | Q28484277 | ||
| A semiempirical free energy force field with charge-based desolvation | Q29614316 | ||
| Drug combination studies and their synergy quantification using the Chou-Talalay method | Q29617422 | ||
| Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase | Q29619994 | ||
| Dihydro-alkylthio-benzyl-oxopyrimidines as inhibitors of reverse transcriptase: synthesis and rationalization of the biological data on both wild-type enzyme and relevant clinical mutants. | Q31138625 | ||
| Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients | Q33714377 | ||
| Synthesis and biological evaluation of novel dihydro-aryl/alkylsulfanyl-cyclohexylmethyl-oxopyrimidines (S-DACOs) as high active anti-HIV agents | Q33782941 | ||
| Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine | Q33953120 | ||
| Anti-human immunodeficiency virus type 1 activity of novel 6-substituted 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives | Q34145448 | ||
| Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. | Q34910804 | ||
| Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). | Q35005228 | ||
| Human immunodeficiency virus reverse transcriptase: 25 years of research, drug discovery, and promise | Q36435971 | ||
| Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase | Q37099790 | ||
| Recent advances in the DABOs family as potent HIV-1 non-nucleoside reverse transcriptase inhibitors | Q37875172 | ||
| 2011 update of the drug resistance mutations in HIV-1. | Q37966667 | ||
| Dihydro-alkoxyl-benzyl-oxopyrimidine derivatives (DABOs) as non-nucleoside reverse transcriptase inhibitors: an update review (2001-2011). | Q37982772 | ||
| The development of HEPT-type HIV non-nucleoside reverse transcriptase inhibitors and its implications for DABO family | Q38012497 | ||
| Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. | Q38081000 | ||
| Assessing adherence to antiretroviral therapy in randomized HIV clinical trials: a review of currently used methods | Q38086335 | ||
| Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors | Q39522504 | ||
| The anti-HIV activity of three 2-alkylsulfanyl-6-benzyl-3, 4-dihydropyrimidin-4 (3H)-one derivatives acting as non-nucleoside reverse transcriptase inhibitor in vitro. | Q39586664 | ||
| Synthesis and biological evaluation of 6-substituted 5-alkyl-2-(phenylaminocarbonylmethylthio)pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs | Q39591934 | ||
| F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis. | Q39692280 | ||
| Sifuvirtide, a potent HIV fusion inhibitor peptide. | Q39872319 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e81489 | |
| P577 | publication date | 2013-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | DB-02, a C-6-cyclohexylmethyl substituted pyrimidinone HIV-1 reverse transcriptase inhibitor with nanomolar activity, displays an improved sensitivity against K103N or Y181C than S-DABOs | |
| P478 | volume | 8 |
| Q28542490 | Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro |
| Q92284526 | Clerodane diterpenoids with potential anti-inflammatory activity from the leaves and twigs of Callicarpa cathayana |
| Q38260066 | Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011-2014). |
| Q50129893 | SJP-L-5 inhibits HIV-1 polypurine tract primed plus-strand DNA elongation, indicating viral DNA synthesis initiation at multiple sites under drug pressure. |
| Q35859394 | SJP-L-5, a novel small-molecule compound, inhibits HIV-1 infection by blocking viral DNA nuclear entry |
| Q38746848 | Synthesis and Anti-HIV-1 Activity Evaluation for Novel 3a,6a-Dihydro-1H-pyrrolo[3,4-c]pyrazole-4,6-dione Derivatives. |
| Q90094399 | Synthesis and biological evaluation of a series of 2-(((5-akly/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3H)-ones as potential HIV-1 inhibitors |
Search more.